ArticleActa pharmaceutica Sinica. B2023

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria.

Yixiang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.